Search details
1.
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
J Neurol Neurosurg Psychiatry
; 2024 Jan 19.
Article
in English
| MEDLINE | ID: mdl-38242680
2.
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
J Neurol Neurosurg Psychiatry
; 2024 Mar 07.
Article
in English
| MEDLINE | ID: mdl-38453478
3.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 Mar 27.
Article
in English
| MEDLINE | ID: mdl-38538060
4.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37068931
5.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37414534
6.
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Mult Scler
; 29(14): 1808-1818, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37978852
7.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 93(12): 1330-1337, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36261289
8.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Mult Scler
; 28(5): 842-846, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34882037
9.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
; 28(11): 1752-1761, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35373638
10.
Pregnancy-induced brain magnetic resonance imaging changes in women with multiple sclerosis.
Eur J Neurol
; 29(5): 1446-1456, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35015921
11.
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.
Eur J Neurol
; 29(4): 1082-1090, 2022 04.
Article
in English
| MEDLINE | ID: mdl-33724638
12.
Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis.
BMC Neurol
; 22(1): 270, 2022 Jul 19.
Article
in English
| MEDLINE | ID: mdl-35854235
13.
The clinical and paraclinical correlates of employment status in multiple sclerosis.
Neurol Sci
; 43(3): 1911-1920, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34392392
14.
Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis.
Int J Neurosci
; 132(7): 724-734, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-33059501
15.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
PLoS Med
; 17(10): e1003348, 2020 10.
Article
in English
| MEDLINE | ID: mdl-33125391
16.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler
; 26(1): 79-90, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31397221
17.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 90(4): 458-468, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30636699
18.
Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?
J Neural Transm (Vienna)
; 126(6): 731-737, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31098724
19.
Brain MRI disease burden and sex differences in cognitive performance of patients with multiple sclerosis.
Acta Neurol Belg
; 124(1): 109-118, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37552396
20.
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Lancet Child Adolesc Health
; 8(5): 348-357, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38547883